ERBB2 and lung cancer: Such an autonomous invasive/metastatic property of Her2/GEP100-overexpressing lung cancers, as well as frequent existence of their node-metastasis already at the time of surgery, appears to be a part of the reason as to why Trastuzumab does not exhibit clear survival benefits in patients with this disease.